Login to Your Account

Basilea Teams up with Astellas in $500M-Plus Antifungal Deal

By Jennifer Boggs

Thursday, February 25, 2010
With the ink still drying on its termination agreement with Johnson & Johnson for troubled antibiotic ceftobiprole, Basilea Pharmaceutica AG landed a lucrative partnership for its late-stage antifungal product isavuconazole. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription